SOURCE-LINKED STUDY SUMMARY
The Discovery and Development of Liraglutide and Semaglutide.
Abstract summarizedQuality not appraised
- What was studied
- This review traces the discovery and development of liraglutide and semaglutide, rather than reporting a new clinical trial.
- Who / model studied
- It discusses human and non-human research, including people with type 2 diabetes and obesity.
- Studied dose & schedule
- Dose and schedule were not reported in the source used for this summary.
- What the study found
- Albumin binding helped extend drug action while retaining receptor activity. The review describes pancreatic and brain receptor effects on glucose control and weight, and cardiovascular benefits in diabetes; the cardiovascular mechanism remained uncertain.
- Limitations & context
- Study limitations were not stated in the abstract. Methodological quality has not been appraised.
Read summary source ↗ · Prepared 9/24/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.3389/fendo.2019.00155